TAK vs. ZTS: Takeda Pharmaceutical vs. Zoetis Stock Comparison

Company Profile

Takeda Pharmaceutical (TAK) and Zoetis (ZTS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Zoetis (ZTS) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Zoetis (ZTS) has a non-negative beta of 0.66.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Zoetis (ZTS) at 57.63% sits in the top ROE quartile, while Takeda Pharmaceutical (TAK) at 0.56% is closer to the peer norm — stronger capital efficiency for ZTS.

Zoetis (ZTS) at 26.41% converts revenue to bottom-line profit above its industry’s benchmark range, while Takeda Pharmaceutical (TAK) at 0.87% keeps roughly the typical share for its industry.

Both Takeda Pharmaceutical (TAK) at 24.55% and Zoetis (ZTS) at 38.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Zoetis (ZTS) at 2.28% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Takeda Pharmaceutical (TAK) at 77.96% sits in the top EPS growth quartile, while Zoetis (ZTS) at 10.05% is closer to the peer norm — faster per-share earnings growth for TAK.

Growth Metrics

Financial Strength

Both Takeda Pharmaceutical (TAK) at 1.15 and Zoetis (ZTS) at 2.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but ZTS is more stretched: Takeda Pharmaceutical (TAK) at 0.72 sits in the higher-leverage quartile and Zoetis (ZTS) at 2.80 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Both Takeda Pharmaceutical (TAK) at 953.28% and Zoetis (ZTS) at 2.55% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Zoetis (ZTS) reports 35.24%, ranking against industry peers normally.

Dividend Metrics

Valuation

Zoetis (ZTS) at 13.50 is near its industry’s usual P/E ratio, while Takeda Pharmaceutical (TAK) at 300.29 sits above its peer range — an unusually expensive price for TAK’s trailing earnings.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while Zoetis (ZTS) at 3.40 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 looks cheap against book in the lower P/B ratio quartile, while Zoetis (ZTS) at 9.80 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics